A foundational shift in how biology is measured

Nano Performance Technologies is a Purdue-derived 2D semiconductor platform enabling scalable multi biomarker detection without redesign at each new target. The platform supports 14 validated biomarkers today and is expanding toward a 100+ marker library, unlocking continuous biological data from a single system, built from millions in non dilutive funding and validated research.

View the Raise Platform Overview

Validated Biomarkers

$4M+

Non Dilutive Funding

$1.5M

Raising Now

$30M

Pre-Money Valuation

Biosensing is shifting from single analyte systems to semiconductor based multi biomarker platforms.

Platforms that scale across biomarkers without redesign win. NPT is that platform.

The Problem & Our Answer

Single analytes are a dead end

Biosensing has been locked into narrow, single-target architectures for decades. Every new biomarker required years of development and significant capital. That era is ending.

The Old Constraint

One biomarker at a time

Existing biosensor companies are constrained to single-target sensing systems — like glucose monitors — that must be entirely rebuilt for each new biological target. Expanding has historically required multi-year development cycles and capital-intensive redesigns. There is no path to platform scale from these architectures.

The NPT Approach

A semiconductor architecture that compounds

NPT's 2D semiconductor platform supports 14 validated biomarkers today — and the library expands without requiring device-level redesign. Each new biomarker adds to the same foundation. The same architecture that detects neurotransmitters in sweat today will power clinical-grade microneedle devices, licensing deals, and AI data infrastructure tomorrow. NPT's semiconductor materials introduce unique surface chemistry, enabling biological signal transduction with levels of sensitivity and reliability not achievable through conventional sensing approaches.

TellU Sense · 2D semiconductor platform → continuous biological data

The Product

From semiconductor platform to wearable reality

The TellU Sense device is the first commercial expression of the NPT platform — a wearable biosensor that reads multiple biological signals in real time through sweat, with a clear pathway to FDA-grade microneedle devices.

Multi-biomarker sensing14 lab-validated markers readable from a single wearable form factor
Surface chemistry advantageUnique 2D semiconductor surface chemistry enables signal transduction not achievable with conventional approaches
Real-time signal transductionContinuous biological monitoring, not episodic snapshots
Expansion towards 100+Platform architecture scales the biomarker library without device redesign — a foundational shift in sensing

Revenue Architecture

Four compounding revenue layers

This is not a single-product company. Each layer reinforces the others — creating a platform business that compounds as the biomarker library grows.

Licensing Engine

Biomarker capabilities and platform access licensed to wearables, diagnostics, and biosensor companies. Structured deals target the $50M–$500M range as the library expands.

Primary

In-House Products

TellU Sense wearable systems — sweat-based market entry (non-FDA) with FDA microneedle optionality extending into clinical-grade devices.

Near-term

Efficacy Standard Layer

Real-time biological validation for pharmaceuticals and nutraceuticals. Positioned to become a new industry standard for efficacy measurement.

Emerging

AI Data Infrastructure

Live human biological data at scale — high-value datasets for AI models that cannot rely on synthetic data. A new category of data asset.

Long-term

The platform also extends beyond biosensing into next-generation electronics and advanced semiconductor applications, with a growing portfolio of quantum materials IP. Biosensing is the initial market entry, not the ceiling.

Traction

The science is validated. The commercial pipeline is open.

Technology validated through funded research, lab testing, and early human trials.

Real-time neurotransmitter detection in human sweat

Demonstrated multi-neurotransmitter detection in human subjects — a milestone no competitor has reached with a scalable architecture.

14 biomarkers validated across the platform

Lab-validated across a growing biomarker library, each supported by the same underlying semiconductor architecture.

Purdue-backed research and federal funding

Over $4M in non-dilutive funding from USAF, DoD, DOE, and NSF has de-risked the core technology. We are not funding discovery — we are funding execution.

Corporate VC and strategic discussions active

In active discussions with multiple corporate development groups across semiconductor and medtech, many of whom have expressed interest in leading a future Series A.

$1M

First Paid Pilot — Active Discussions

Pilot pathway potential ~$10M

Target Series A range $75M–$300M

Licensing deal range $50M–$500M

Investment bank discussions Active

Public market pathway (SPAC / IPO) Under evaluation

Competitive Landscape

Comparable companies raised more with less

The biosensing market has seen $10M–$300M+ rounds for companies with fewer validated biomarkers, no scalable platform, and no underlying semiconductor IP. NPT enters at a fraction of that cost basis.

Company	Architecture	Biomarkers	Scalable Platform	Semiconductor IP	Revenue Status	Capital Raised
NPT (us)	2D Semiconductor	14 validated	✓	✓	Pre-revenue	$1.5M (raising)
Typical Biosensor Co.	Biorecognition-limited	1–3	—	—	Pre-revenue	$10M–$100M+
Wearable Biosensor Co.	Single-analyte	1	—	—	Pre-revenue	$50M–$300M+
Diagnostics Platform	Enzyme-coupled electrochemical	3–5	Partial	—	Early revenue	$30M–$150M+

Competitive landscape is illustrative based on publicly available funding data from comparable biosensing ventures. Specific company names withheld.

The Raise

$1.5M at $30M pre-money. Before the re-pricing.

This round funds execution, not discovery. Investors are entering at the earliest commercialization inflection — before revenue visibility, before licensing scale, before product launch.

Valuation

$30M

Pre-Money

Comparable companies have raised $10M–$300M+ at equivalent or later stages with fewer biomarkers, no scalable platform, and no underlying semiconductor IP — while remaining pre-revenue. NPT enters at a fraction of that cost basis.

Amount

$1.5M

Strategic Bridge

This round is designed to unlock a significant re-pricing event, positioning the company for a Series A in the $75M–$300M range.

First ~$1M paid pilot execution
Product deployment
Clinical positioning
Conversion into larger licensing deals

Entry Point

Now

Investors are entering before: revenue visibility — licensing scale — product launch. This is one of the last entry points before commercial launch and the associated valuation re-pricing.

Technology is de-risked
Platform is built
Human trials complete
Commercial demand emerging

Path Forward

Series A

$75M–$300M Target Range

Already in discussions with multiple corporate VC and corporate development groups across semiconductor and medtech. Active dialogue with investment banks and SPAC sponsors as part of a long-term capital markets strategy.

Investor Fit

This is a deep tech investment.

Be clear-eyed about what this is and what it isn't.

This is for you if

You believe semiconductor-based biosensing is the future

You are a patient, thesis-driven investor comfortable with pre-revenue deep tech. You understand platform value, IP moats, and the upside of entering before commercial scale. You want to be in before the repricing.

This is not for you if

You need de-risked SaaS metrics today

If you require current revenue, proven commercial scale, or near-term liquidity, this is not the right opportunity. We are pre-revenue and early in commercialization. The upside is real — but it requires conviction at this stage.

Team

Deep science. Commercialization focus.

This is not an abstract research effort. NPT combines Purdue-grade technical depth with capital markets and strategic execution expertise.

Founder

Capital Markets & Deep Tech Commercialization

Capital markets and deep tech commercialization background, with experience in deal origination, partnerships, and strategic execution in advanced technologies.

Scientific Leadership

Purdue-Based Expertise

Multi-award winning Purdue-based expertise in biosensing, 2D materials, and semiconductor systems. Directly responsible for the $4M+ in federal non-dilutive funding and the 14-biomarker validated platform.

Translational Expertise

Clinical & Regulatory Experience

PhD-level biosensor scientist with direct experience advancing continuous monitoring systems through clinical development and regulatory pathways, including major contributions to widely deployed large commercial biosensor platforms.

A combination of deep technical capability, real-world biosensor deployment experience, and dynamic corporate vision with commercialization focus.